After Latest Adalimumab CRL, Alvotech Gets Another New Quality Chief
Sarah Tanksley, Appointed In October, Replaced By Sandra Casaca At Biosimilars Firm
Six months after replacing its chief quality officer, biosimilars specialist Alvotech has again appointed a new head of quality, in the wake of the latest US FDA knockback for its AVT02 proposed adalimumab biosimilar rival to Humira.
